Tower Research Capital LLC (Trc) Bei Gene, Ltd. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,391 shares of BGNE stock, worth $304,211. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,391
Previous 8,331
83.3%
Holding current value
$304,211
Previous $1.19 Million
73.74%
% of portfolio
0.01%
Previous 0.02%
Shares
28 transactions
Others Institutions Holding BGNE
# of Institutions
253Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.31 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.41 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.13 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1.09 Billion0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$810 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.7B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...